SMS Pharma Announces 38th AGM on Sep 23, 2026, via Video Conference
SMS Pharmaceuticals Limited will hold its 38th AGM on September 23, 2026, via video conference. The record date for dividend entitlement is September 16, 2026. Shareholders must submit declarations by September 9, 2026.
This is a standard procedural announcement regarding the Annual General Meeting and does not have a direct material impact on the company's operations or financial standing.
The announcement is a routine corporate event (AGM notification) and does not contain any new financial results or significant business developments that would sway the sentiment.
SMS Pharmaceuticals Limited has announced that its 38th Annual General Meeting (AGM) will be held on Wednesday, September 23, 2026, at 11:00 a.m. IST. The meeting will be conducted through Video Conference or Other Audio Visual Means, in compliance with the circulars issued by the Ministry of Corporate Affairs (MCA) and the Securities and Exchange Board of India (SEBI).
The notice of the AGM and the Annual Report for the financial year 2025-26, including the financial statements for the year ended March 31, 2026, will be sent to all members whose email addresses are registered with the Company or their Depository Participants. For shareholders who have not registered their email addresses, a letter providing the weblink and exact path for accessing the Annual Report for FY 2025-26 will be sent.
Members can join and participate in the AGM through the Video Conference/Other Audio Visual Means facility. The record date for determining entitlement to the final dividend for the financial year ended March 31, 2026, if approved at the AGM, is September 16, 2026. Shareholders are advised to submit applicable declarations and update their bank account details for direct dividend receipt by September 9, 2026. The newspaper advertisement regarding the AGM has been published in the Financial Express (English) and Nava Telangana (Telugu).
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.